Valuation: Altimmune, Inc.

Market Cap 632M 551M 521M 473M 886M 60.66B 889M 6.24B 2.41B 30.84B 2.37B 2.32B 99.23B P/E 2026 *
-5.55x
P/E 2027 * -4.96x
Enterprise Value 192M 167M 158M 143M 269M 18.39B 270M 1.89B 730M 9.35B 720M 704M 30.09B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.31%
1 week-0.61%
Current month+4.50%
1 month+9.43%
3 months+20.37%
6 months-4.97%
Current year-9.97%
1 week 3.18
Extreme 3.18
3.36
1 month 2.92
Extreme 2.92
3.55
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 A Exercice

Executive/Senior Manager

54,826 0.0282%
8/13/26 A Buy

Chief Executive Officer

15,000 0.0077%
7/31/26 A Free

Chief Financial Officer

1,753 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%-0.61%-16.02%+19.93% 632M
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.50%+1.42%+31.89%+190.02% 27.55B
Weighted average by Cap. -0.47%+1.44%+36.39%+147.68%

Financials

2026 *2027 *
Net sales - -
Net income -100M -87.63M -82.74M -75.13M -141M -9.64B -141M -991M -382M -4.9B -377M -369M -15.77B -123M -107M -101M -92.08M -173M -11.82B -173M -1.21B -469M -6.01B -463M -452M -19.33B
Net Debt -440M -384M -363M -329M -617M -42.27B -620M -4.34B -1.68B -21.49B -1.65B -1.62B -69.15B -332M -289M -273M -248M -465M -31.83B -467M -3.27B -1.26B -16.18B -1.25B -1.22B -52.07B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
18/09/26 $3.250 +0.31% 12,176,850
17/09/26 $3.240 0.00% 3,457,393
16/09/26 $3.240 +0.31% 3,331,820
15/09/26 $3.230 -2.12% 2,339,114
14/09/26 $3.300 +0.92% 2,465,554
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.250USD
Average target price
17.22USD
Spread / Average Target
+429.91%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!